CER Checklist for EU MDR: A Practical Framework for Clinical Evaluation Report Pre-Submission Review

EU MDR CER Checklist: What to Review Before Submitting Your Clinical Evaluation Report

Clinical Evaluation Reports are central to demonstrating the safety and performance of medical devices under EU MDR 2017/745. The evidence presented within a CER must not only support clinical claims but also align with post-market data and withstand detailed scrutiny during regulatory review.

Within the EU MDR framework, expectations for clinical evaluation extend beyond the presence of data to how that data is identified, evaluated, and integrated across the broader evidence lifecycle. Challenges in CER quality are often linked to misalignment between data sources, gaps in methodological transparency, and inconsistencies across documentation – issues that may only become apparent during Notified Body assessment.

This checklist functions as a practical CER framework for pre-submission review, supporting the consistent application of established methodologies and helping to identify gaps in evidence, documentation, or alignment before they become apparent during regulatory review.

How to Use The CER Checklist

This checklist is intended as a practical tool to support the review and refinement of Clinical Evaluation Reports under EU MDR. It may be applied during pre-submission review, internal audits, or routine updates to ensure that key elements of clinical evaluation remain aligned and adequately documented throughout the device lifecycle.

The checklist should not be viewed as a substitute for a structured CER writing process or clinical evaluation methodology. Rather, it supports the consistent application of established approaches, helping to identify gaps in evidence, documentation, or alignment before they become apparent during regulatory review.

CER Checklist for EU MDR

CER Pre-Submission Review Flow

Pre-submission review pathway for assessing CER quality under EU MDR

A. Evidence Foundation

Clinical strategy clearly defined

A clear clinical strategy forms the foundation of a robust Clinical Evaluation Report. The intended use, clinical claims, and target population should be consistently defined and reflected across all elements of the evaluation.

Clinical strategy is defined within the Clinical Evaluation Plan (CEP), as required under Annex XIV of EU MDR. The CEP establishes the scope, methodology, and data sources for the evaluation, providing a structured basis for how clinical evidence will be identified and assessed. Where this foundation is not clearly defined, inconsistencies may arise between the planned evaluation and the conclusions presented within the CER — a common reason Clinical Evaluation Reports are challenged during Notified Body review.

Literature search structured and reproducible

The literature search underpinning the CER should follow a predefined and well-documented methodology. This includes clearly defined databases, search terms, filters, and inclusion and exclusion criteria, allowing the process to be reproduced and independently verified.

A structured approach supports transparency and traceability, both of which are essential requirements under EU MDR. Where search strategies are not adequately documented, the reliability of the evidence base may be questioned during regulatory assessment. CER medical writing that relies on poorly documented search methodology is one of the most frequently identified gaps in Notified Body review.

A systematic approach to literature review is aligned with expectations outlined in MEDDEV 2.7/1 Rev. 4 and relevant MDCG guidance, which continue to inform best practices for CER writing and clinical evaluation methodology under EU MDR.

B. Evaluation Quality

Critical appraisal of clinical evidence

The identification of relevant literature is only one component of CER writing. Included studies should be assessed in a structured and transparent manner for quality, relevance, and potential risk of bias.

Without appropriate critical appraisal, the clinical evidence base may lack depth and context. This can result in conclusions that are not sufficiently supported, reducing confidence in the overall Clinical Evaluation Report and increasing scrutiny from Notified Bodies. Where critical appraisal is absent or superficial, CERs risk being descriptive rather than analytical – summarising studies individually rather than synthesising them into a coherent clinical argument.

Positioning within the state of the art (SOTA)

CER writing should position the subject device within the current state of the art, taking into account comparable devices, available treatment options, and established clinical practice.

Clear contextualisation supports a balanced and well-justified assessment of clinical performance and safety. Where the state of the art is not adequately defined, the relevance and completeness of the clinical evaluation may be challenged during review. Defining the state of the art is also essential for demonstrating compliance with Article 61 of EU MDR, which requires that clinical evidence be evaluated in the context of currently available alternatives and accepted standards of care.

C. Lifecycle Alignment

Alignment across CER, PMS, and PMCF activities

Consistency across Clinical Evaluation Reports (CERs), post-market surveillance (PMS), and Post-Market Clinical Follow-Up (PMCF) activities is essential to ensure that safety signals, data interpretation, and conclusions are aligned.

Misalignment across these components may result in inconsistencies in how clinical evidence is presented, increasing the likelihood of questions during regulatory review and requiring additional reconciliation.

Evidence current and actively maintained

Clinical evaluation should be approached as a continuous process, rather than a static exercise. The evidence base should reflect current data, including findings from PMS and PMCF activities, and be updated in line with emerging evidence and regulatory expectations.

Failure to maintain an up-to-date evidence base may lead to inconsistencies across documentation and limit the ability to demonstrate continued safety and performance.

Summary of Key CER Checklist Areas and Common Gaps

Implications for Regulatory Review

Deficiencies identified through checklist-based review often become most apparent during regulatory assessment, where both the clinical evidence and the processes used to generate it are subject to detailed scrutiny. Gaps in CER methodology, inconsistencies across documentation, or insufficient justification of conclusions may prompt formal deficiency letters from the Notified Body, outlining areas requiring clarification, additional evidence, or further justification, typically with defined timelines for response.

In practice, these observations may lead to delays in review timelines, increased workload to address identified gaps, and difficulty demonstrating that the benefit-risk profile of the device is adequately supported. Where inconsistencies extend across Clinical Evaluation Reports, post-market surveillance, and PMCF activities, the effort required to reconcile these differences may be substantial.

Regulatory review under EU MDR considers not only the presence of clinical data but also the transparency, traceability, and consistency of the processes used to generate and evaluate it. A structured and well-aligned CER is therefore essential to support a clear and defensible regulatory submission.

Checklist as a Support Tool, Not a Substitute for Process

A structured CER checklist supports the consistent application of clinical evaluation requirements, helping to ensure that key elements are addressed and appropriately documented under EU MDR. It does not, however, compensate for gaps in underlying CER writing methodology or clinical judgement.

Effective clinical evaluation under EU MDR requires the systematic identification, appraisal, and integration of clinical data, supported by clearly defined procedures and appropriate clinical and regulatory expertise. The checklist functions as a complementary tool, reinforcing established practices and supporting transparency, consistency, and alignment across the evaluation process.

Conclusion

A well-structured Clinical Evaluation Report is not defined solely by the completeness of its content, but by the consistency, alignment, and transparency of the processes used to generate and maintain it. Under EU MDR, expectations for CER writing extend beyond data collection to how evidence is systematically identified, appraised, and integrated across the product lifecycle.

The checklist outlined in this article provides a practical framework for assessing key elements of clinical evaluation prior to submission and during ongoing updates. When applied within a methodologically sound CER writing process supported by appropriate expertise, it can strengthen the overall quality and defensibility of the submission.

If you are preparing a Clinical Evaluation Report or conducting a pre-submission review, Citemeds supports medical device manufacturers with CER writing, literature review, and clinical evaluation services aligned with EU MDR expectations. Get in touch to discuss your requirements.

FAQs

What should a CER checklist include under EU MDR?

A CER checklist for EU MDR should cover six key areas: a clearly defined clinical strategy including intended use and clinical claims; a structured and reproducible literature search methodology; critical appraisal of included clinical evidence; positioning of the device within the current state of the art; alignment across CER, PMS, and PMCF documentation; and confirmation that the evidence base is current and actively maintained. Each of these areas corresponds to requirements under EU MDR 2017/745 and MEDDEV 2.7/1 Revision 4.

How often should a Clinical Evaluation Report be reviewed?

Under EU MDR, a Clinical Evaluation Report must be reviewed and updated regularly throughout the device lifecycle — not only at the point of initial submission. Updates are required when new post-market surveillance or PMCF data becomes available that could affect the evaluation’s conclusions. For higher-risk devices, this typically means annual reviews. Using a structured CER checklist during each update cycle helps ensure that key elements remain aligned and adequately documented.

What is the Clinical Evaluation Plan, and how does it relate to the CER?

The Clinical Evaluation Plan (CEP) is the document that defines the scope, methodology, and evidence requirements for the clinical evaluation — including intended use, clinical claims, and the planned literature search strategy. It is required under Annex XIV of EU MDR. The Clinical Evaluation Report is the output document that presents the results of the evaluation conducted in line with the CEP. The CER should demonstrate that the methodology defined in the CEP was followed consistently — any misalignment between the two is a common source of challenge during Notified Body review.

What is the state of the art in a CER and why does it matter?

The state of the art refers to the current standard of care in the relevant clinical field — including comparable devices, available treatment alternatives, and established clinical practice. Under Article 61 of EU MDR, clinical evidence must be evaluated in the context of currently available alternatives. A CER that does not adequately define and position the device against the state of the art is frequently challenged during regulatory review, as it limits the ability to demonstrate that the device’s benefit-risk profile is acceptable relative to existing options.

What are the most common gaps identified in CERs during Notified Body review?

The most common gaps identified during Notified Body review of Clinical Evaluation Reports include insufficient or poorly documented literature search methodology, lack of structured critical appraisal of included studies, inadequate state-of-the-art analysis, inconsistencies between the CER and PMS or PMCF documentation, and an outdated evidence base that does not reflect recent post-market data. These gaps are typically communicated through formal deficiency letters outlining areas requiring clarification or additional evidence before the submission can progress.

Can a checklist replace a structured clinical evaluation process?

No. A CER checklist is a support tool — not a substitute for a structured clinical evaluation process. It helps identify gaps in evidence, documentation, and alignment before they become apparent during regulatory review, but it does not compensate for weaknesses in underlying methodology or clinical judgement. Its value lies in reinforcing established practices and supporting consistency across the evaluation process when used alongside appropriate clinical and regulatory expertise.

What is the difference between a CER and a PMCF report?

A Clinical Evaluation Report synthesises all available clinical evidence — including literature, clinical investigation data, and post-market data — to demonstrate the safety and performance of a device at a point in time. A PMCF report is a specific post-market document that presents the findings of Post-Market Clinical Follow-Up activities — structured data collection conducted after the device has reached the market. PMCF findings feed directly into the CER, which must be updated to reflect new evidence emerging from PMCF and PMS activities throughout the device lifecycle.